Amniotic Products Market

Amniotic Products Market by Type (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospital & Ambulatory Surgical Centers) - Global Forecast to 2028

Report Code: MD 7637 Jul, 2023, by marketsandmarkets.com

The global amniotic products market in terms of revenue was estimated to be worth $900 million in 2023 and is poised to reach $1,289 million by 2028, growing at a CAGR of 7.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by the increased outsourcing of bio decontamination services and Growing healthcare sector and increasing outsourcing in emerging economies. However, Challenges associated with Variability of pathogen resistance may threat the growth of this market.

Attractive Opportunities in the Amniotic Products Market

Amniotic Products Market

To know about the assumptions considered for the study, Request for Free Sample Report

Amniotic Products Market

Recession Impact on the Amniotic Products Market

The impact of a global recession can vary across different regions and countries. Economic conditions, healthcare systems, and regulatory environments differ worldwide, and the severity and duration of the recession will also influence the extent of its impact on the amniotic membranes market globally. During a global recession, the amniotic membranes market could experience several potential impacts. Such as During a recession, healthcare budgets may be reduced as governments and individuals prioritize essential needs. This can lead to a decrease in demand for amniotic membranes as healthcare providers face financial constraints, Economic downturns often result in increased price sensitivity among healthcare providers and consumers. Manufacturers and suppliers of amniotic membranes may face pricing pressure as healthcare organizations seek more cost-effective alternatives or negotiate lower prices, in a recession, individuals may delay or forgo elective medical procedures due to financial constraints. This can impact the demand for amniotic membranes, particularly in procedures such as wound healing, tissue repair, or ophthalmic surgeries.

Amniotic Products Market Dynamics

DRIVER: Growth in the target patient population

Physical health conditions, such as chronic diseases, have a negative effect on the wound healing process. For instance, diabetes and obesity can result in an increased incidence of ulcerations, such as leg or foot ulcers, which would require wound treatment and incur exorbitant medical expenses.

As per the IDF 2021, 537 million adults (20-79 years) are living with diabetes (1 in 10). This number is estimated to rise to 643 million by 2030 and 783 million by 2045. Diabetic foot ulcers occur because of major complications of diabetes. Nearly 15% of the total diabetic population suffers from diabetic foot ulcers (Source: Cellular and Molecular Basis of Wound Healing in Diabetes by Brem H., Journal of Clinical Investigation). An article published in the Journal of Foot and Ankle Research estimates that more than 10% of people with type 2 diabetes mellitus are highly prone to foot ulcers, with a lifetime risk of 15%. Thus, the increasing incidence of diabetes will correspondingly drive the demand for wound care products. As the wound healing process is slower in diabetes, advanced wound care products such as amniotic membranes are required for treatment.

Amniotic membranes are also useful in the management of many ocular conditions. Amniotic membranes are widely used for eye surgeries and the treatment of an increasing number of ocular surface pathologies such as ulcers of the cornea or conjunctiva, or in other cases, severe dry eyes.

According to the American Academy of Ophthalmology, the annual incidence of corneal ulcers in the US ranges between 30,000 and 75,000.

According to the National Eye Institute, by 2050, the number of people with cataracts in the US is estimated to double from 24.4 million to about 50 million.

The growth of the target patient population and the subsequent increase in the number of target medical procedures is expected to play a key role in the increased adoption of amniotic products.

Obesity leads to various critical conditions, wounds, and infections, which lead to surgeries and infectious wounds. Such conditions, along with comorbidities like diabetes, lead to non-healing/long-term chronic wounds. Such wounds are highly susceptible to developing infections more than once and need wound care treatments and devices for enhanced wound healing and successful recovery.

Obesity is now termed a worldwide epidemic; approximately 57.8% of all adults will be obese by 2030 (Source: WHO, 2020). Similarly, more than 1 billion people worldwide are obese 650 million adults, 340 million adolescents and 39 million children. This number is still increasing. WHO estimates that by 2025, approximately 167 million people adults and children will become less healthy because they are overweight or obese. (Source: WHO, 2022).

 As per the World Obesity Atlas 2022, estimation, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. Moreover, according to the WHO, as of 2019, an estimated 38.2 million children under the age of five years were reportedly overweight/obese. Obesity is an epidemic in low- and middle-income countries as well. In 2019, the prevalence of childhood obesity in Africa increased by approximately 24% since 2000. Considering this constantly increasing trend of obesity across all age groups and genders, it is anticipated that the associated wounds, infections, and critical illnesses/surgeries will also increase. This will result in the increasing demand for amniotic products during the forecast period.

OPPORTUNITY: Emerging economies

Emerging countries such as China, India, South Korea, Brazil, and Mexico offer significant growth opportunities to major players functioning in the amniotic products industry. This can be attributed to low regulatory barriers, improvements in healthcare infrastructure, growing patient population, and rising healthcare expenditure. Moreover, regulatory policies in the Asia Pacific region are more adaptive and business-friendly in comparison to those of developed countries. This factor, in addition to the increasing competition in mature markets, has drawn key players in the market to focus on the emerging economies.

China is a prominent market for amniotic products, owing to its recent infrastructural improvements, rapid economic growth, rising domestic demand, and public-private initiatives to support healthcare research. Similarly, the Indian market reported an increasing prevalence of target diseases and a fast-growing healthcare industry, coupled with a shift towards advanced treatment options.

  • In China, the population suffering from diabetes is projected to reach 140.5 million by 2030 from 116.4 million in 2019.
  • Diabetes prevalence in % of the population ages 20 to 79 in China was 10.6% in 2021 (Source: The World Bank). 
  • The China' healthcare expenditure per capita was increased from USD 539.62 in 2019 to USD 583.43 in 2020 (Source: The World Bank).
  • The India' healthcare expenditure per capita was increased from USD 44.9 in 2010 to USD 56.63 in 2020 (Source: The World Bank).
  • To capitalize on the growth opportunities offered, prominent players in the market are focusing on enhancing their presence in emerging countries.
  • In January 2020, LifeCell International Pvt. Ltd. (India) received accreditation from the American Association of Tissue Banks (AATB) for its birth tissue products. The company plans to launch Amchoplast in India. Amchoplast is a minimally manipulated and aseptically processed dehydrated human amnion-chorion tissue allograft used for wound healing applications as it enhances the healing mechanism, reduces scar tissue formation, and modulates inflammation of the wound.
  • Compared to Europe and North America, the Asia Pacific and Latin America are relatively untapped markets for amniotic products and have huge growth potential. Owing to this, various players are focusing on increasing their presence in these regions.

CHALLENGE: High cost of amniotic membrane products

The high cost of amniotic products and their associated treatments can be a significant concern for patients, healthcare providers, and healthcare systems.  As per the article published by American Optometric Association, Amniotic membranes can cost from USD 300 to USD 900 per device which can be a significant problem for patients. Similarly, purchase price for the physician can range from USD 125 to USD 900 (Source: Modern Optometry 2021). Likewise, the average 1 year per patient medical cost of DFUs is estimated at USD 28,000 where amniotic membranes are being used to improve healing rates in diabetic foot ulcers. Some of the other factors contribute to the high cost which are listed below.

Processing and Manufacturing: Amniotic products require specialized processing and manufacturing techniques to preserve their biological properties and ensure safety. These processes involve extensive quality control, testing, and regulatory compliance, which can increase the overall cost of production.

Donor Screening and Testing: Donor screening and testing are essential to ensure the safety and quality of amniotic products. Extensive testing for infectious diseases and genetic abnormalities adds to the cost of processing and manufacturing.

Storage and Logistics: Proper storage and transportation of amniotic products require specific conditions, such as controlled temperatures and specialized packaging. These requirements increase the cost of storage, distribution, and logistics.

Research and Development: The development of amniotic products involves significant research and development efforts, including preclinical studies and clinical trials. The costs associated with research, obtaining regulatory approvals, and ensuring compliance with applicable regulations contribute to the overall cost.

Limited Supply: The availability of amniotic products is often limited due to the challenges associated with donor tissue procurement and processing. Limited supply and high demand can drive up the cost of these products.

Regulatory Compliance: Compliance with regulatory requirements and quality standards adds to the cost of manufacturing and distribution. Meeting the necessary regulatory standards and maintaining ongoing compliance require dedicated resources and infrastructure.

Reimbursement Challenges: Reimbursement for amniotic products and their associated treatments can be challenging. Insurance coverage and reimbursement policies may vary, and obtaining adequate reimbursement for these products can be complex, potentially increasing the cost burden for patients and healthcare providers.

US accounted for the largest share of the North American amniotic products industry in 2022.

Based on the region, the North American amniotic products market is segmented into US and Canada. In 2022, the US accounted for the largest share of the North American market. Growth in this market can be attributed to presence of stringent regulatory standard, rising healthcare expenditure, the increasing number of surgical procedures performed in the US, the rising geriatric population, the high prevalence of chronic wounds and diabetes, and the strong presence of amniotic product manufacturers.

Japan registered the highest growth rate in Asia Pacific amniotic products industry.

The APAC amniotic products market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the highest growth rate of the Asian market. The high growth rate of Japan can be attributed to the presence of a well-established healthcare sector and the rapidly increasing geriatric population. An increase in the number of elderly people gives rise to various orthopedic and ophthalmological diseases which is highly susceptible to several diseases and disorders. Therefore, growth in this population segment will directly drive the demand for effective and efficient wound care biologics, including amniotic products.

The UK in European amniotic products industry to witness the growth rate during the forecast period.

The Europe amniotic products market is segmented into Germany, France, the UK, and the Rest of Europe. Germany is registered the highest growth rate during the forecast period. The major factors contributing to the growth of this market are the high prevalence of diabetes and venous ulcers, rising in ophthalmic, orthopedic & wound cases in the UK, increasing R&D activities, strategic developments by key players, and the growing geriatric population.

Amniotic Products Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some of the major players operating in this market are mimedx (US), Organogenesis Inc. (US), Smith+Nephew (UK), Integra LifeSciences (US). In 2022, mimedx (US), held the leading position in the market. The company’s large share can be attributed to its broad range of amniotic-based products. Smith+Nephew (UK), held the second position in the amniotic products market in 2022.

Scope of the Amniotic Products Industry

Report Metric 

Details 

Market Revenue in 2023

$900 million

Projected Revenue by 2028

$1,289 million

Revenue Rate

Poised to Grow at a CAGR of 7.4%

Market Driver 

Growth in the target patient population

Market Opportuity

Emerging economies

This research report categorizes the amniotic products market to forecast revenue and analyze trends in each of the following submarkets:

By Type

  • Cryopreserved Amniotic Membrane
  • Dehydrated Amniotic Membrane

By Application

  • Wound Care
  • Orthopedics
  • Ophthalmology
  • Other Applications

By End User

  • Hospitals, & Ambulatory Surgical Centers
  • Other End Users

By Region

  • North America
  • Europe
  • Apac
  • Latin America
  • Middle East & Africa

Recent Developments of Amniotic Products Industry

  • In 2021, The company VIVEX Biologics (US) launched Cygnus Matrix Disks with the latest configuration of the Cygnus family of amniotic tissue allografts.
  • In 2021, MiMedx (US) received approval from the Japanese Ministry of Health, Labour, and Welfare for the commercialization of EPIFIX in Japan.
  • In 2021, The company Celularity Inc. (US) entered into an exclusive distribution agreement for the commercial distribution rights for orthopedic surgery and sports medicine products with Arthrex, Inc. (US).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 22)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
          FIGURE 1 AMNIOTIC PRODUCTS INDUSTRY SEGMENTATION
           1.3.1 REGIONS CONSIDERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
    1.6 LIMITATIONS 
    1.7 RECESSION IMPACT 
    1.8 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 27)
    2.1 RESEARCH DATA 
          FIGURE 2 AMNIOTIC PRODUCTS MARKET: RESEARCH DESIGN
    2.2 SECONDARY DATA 
           2.2.1 SECONDARY SOURCES
    2.3 PRIMARY DATA 
          FIGURE 3 PRIMARY SOURCES
           2.3.1 KEY DATA FROM PRIMARY SOURCES
           2.3.2 KEY INDUSTRY INSIGHTS
                    FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.4 MARKET SIZE ESTIMATION 
          FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.4.1 GROWTH FORECAST
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
                    FIGURE 7 TOP-DOWN APPROACH
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.6 MARKET SHARE ANALYSIS 
    2.7 RESEARCH ASSUMPTIONS 
    2.8 RESEARCH LIMITATIONS 
    2.9 RISK ASSESSMENT 
    2.10 GROWTH RATE ASSUMPTIONS 
    2.11 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 39)
    FIGURE 9 AMNIOTIC PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 AMNIOTIC PRODUCTS INDUSTRY, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 42)
    4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AMNIOTIC PRODUCTS MARKET 
          FIGURE 13 GROWING TARGET PATIENT POPULATION TO DRIVE MARKET
    4.2 AMNIOTIC PRODUCTS INDUSTRY, BY TYPE 
          FIGURE 14 CRYOPRESERVED AMNIOTIC MEMBRANES SEGMENT TO REGISTER HIGHER CAGR DURING FORECAST PERIOD
    4.3 NORTH AMERICA: MARKET, BY TYPE AND COUNTRY 
          FIGURE 15 US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2022
    4.4 MARKET, BY COUNTRY 
          FIGURE 16 US AND UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 45)
    5.1 INTRODUCTION 
          FIGURE 17 AMNIOTIC PRODUCTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
                    5.2.1.1 Growth in target patient population
                                TABLE 1 GLOBAL PREVALENCE OF DIABETES
                    5.2.1.2 Rising incidence of burn injuries and increasing number of traumatic wounds
                    5.2.1.3 Wound care awareness programs and increasing funding for wound care treatment and management
                                TABLE 2 WOUND CARE AWARENESS INITIATIVES
                                TABLE 3 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY NIH UNDER 21ST CENTURY CURES ACT
                                TABLE 4 FUNDING INITIATIVES FROM CORPORATE PARTNERSHIPS IN 2022 (USD MILLION)
                                TABLE 5 FUNDING FROM CORPORATE PARTNERSHIPS IN 2021 (USD MILLION)
                                FIGURE 18 ARTICLES RELATED TO AMNIOTIC PRODUCTS PUBLISHED DURING 2010–2021
                    5.2.1.4 Increasing number of amniotic membrane transplantations
                                TABLE 6 NUMBER OF AMNIOTIC MEMBRANE TRANSPLANTATIONS PERFORMED IN UNIVERSITY EYE HOSPITAL TÜBINGEN, GERMANY
                    5.2.1.5 Increasing number of ophthalmology, cosmetic, and orthopedic surgeries
                    5.2.1.6 Strategic collaborations and partnerships
                    5.2.1.7 Favorable reimbursement policies
                                TABLE 7 MEDICARE ALLOWABLE AMOUNTS (USD)
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Untapped opportunities in emerging economies
                                TABLE 8 STRATEGIC DEVELOPMENTS IN ASIA PACIFIC
                    5.2.2.2 Implementation of 21st Century Cures Act (US)
                    5.2.2.3 Increasing demand for stem cell research and regenerative medicine
                                FIGURE 19 STEM CELL RESEARCH FUNDING FROM 2011 TO 2020
                                TABLE 9 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)
           5.2.3 CHALLENGES
                    5.2.3.1 Complications and limitations associated with use of amniotic membranes
                    5.2.3.2 Ethical and legal concerns of using amniotic membranes
                    5.2.3.3 High cost of amniotic membrane products
                    5.2.3.4 Competition from alternative therapies
           5.2.4 TRENDS
                    5.2.4.1 Increasing clinical trials for stem cell and chimeric antigen receptor-T cell therapies
                    5.2.4.2 Expanding applications and rising focus on standardization and regulation of amniotic products
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 
           5.3.1 REVENUE SHIFT AND REVENUE POCKETS FOR AMNIOTIC PRODUCT MANUFACTURERS
           5.3.2 REVENUE SHIFT IN AMNIOTIC PRODUCTS INDUSTRY
    5.4 PRICING ANALYSIS 
          TABLE 10 PRICES OF AMNIOTIC PRODUCTS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 20 DIRECT DISTRIBUTION: STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING DEVELOPMENT PHASE
    5.7 ECOSYSTEM ANALYSIS 
           5.7.1 ROLE IN ECOSYSTEM
                    TABLE 11 ROLE OF KEY PLAYERS IN ECOSYSTEM
                    FIGURE 22 KEY PLAYERS IN AMNIOTIC PRODUCTS ECOSYSTEM
    5.8 TECHNOLOGY ANALYSIS 
    5.9 PATENT ANALYSIS 
    5.10 TRADE ANALYSIS 
           TABLE 12 IMPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND)
           TABLE 13 EXPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND)
    5.11 REGULATORY LANDSCAPE 
           5.11.1 NORTH AMERICA
           5.11.2 EUROPE
           5.11.3 EMERGING ECONOMIES
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 14 MARKET: IMPACT OF PORTER’S FIVE FORCES
           5.12.1 INTENSITY OF COMPETITIVE RIVALRY
           5.12.2 BARGAINING POWER OF SUPPLIERS
           5.12.3 BARGAINING POWER OF BUYERS
           5.12.4 THREAT OF SUBSTITUTES
           5.12.5 THREAT OF NEW ENTRANTS
 
6 AMNIOTIC PRODUCTS MARKET, BY TYPE (Page No. - 69)
    6.1 INTRODUCTION 
    6.2 AMNIOTIC MEMBRANES 
          TABLE 15 AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
           6.2.1 CRYOPRESERVED AMNIOTIC MEMBRANES
                    6.2.1.1 Cryopreserved amniotic membranes to dominate amniotic membranes market during forecast period
                                TABLE 16 CRYOPRESERVED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.2 DEHYDRATED AMNIOTIC MEMBRANES
                    6.2.2.1 Logistical advantages of dehydrated amniotic membranes over cryopreserved amniotic membranes to drive demand
                                TABLE 17 DEHYDRATED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 AMNIOTIC PRODUCTS MARKET, BY APPLICATION (Page No. - 74)
    7.1 INTRODUCTION 
    7.2 PRIMARY NOTES 
          TABLE 18 AMNIOTIC PRODUCTS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    7.3 WOUND CARE 
           7.3.1 RISING INCIDENCE OF ULCERS, TRAUMATIC AND SURGICAL WOUNDS, AND BURNS TO DRIVE MARKET
                    TABLE 19 MARKET FOR WOUND CARE, BY REGION, 2021–2028 (USD MILLION)
    7.4 ORTHOPEDICS 
           7.4.1 BENEFITS OFFERED BY AMNIOTIC PRODUCTS FOR ORTHOPEDIC APPLICATIONS TO DRIVE MARKET
                    TABLE 20 MARKET FOR ORTHOPEDICS, BY REGION, 2021–2028 (USD MILLION)
    7.5 OPHTHALMOLOGY 
           7.5.1 LIGHTWEIGHT, THIN, AND ELASTIC NATURE OF AMNIOTIC MEMBRANES TO DRIVE DEMAND IN OPHTHALMOLOGY
                    TABLE 21 MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)
    7.6 OTHER APPLICATIONS 
          TABLE 22 ESTIMATED NUMBER OF COLORECTAL CANCER CASES AND DEATHS IN US IN 2020, BY AGE
          TABLE 23 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
 
8 AMNIOTIC PRODUCTS MARKET, BY END USER (Page No. - 82)
    8.1 INTRODUCTION 
          TABLE 24 AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    8.2 HOSPITALS & AMBULATORY SURGERY CENTERS 
           8.2.1 INCREASING NUMBER OF SURGICAL PROCEDURES TO DRIVE MARKET
                    TABLE 25 MARKET FOR HOSPITALS & ASCS, BY REGION, 2021–2028 (USD MILLION)
    8.3 OTHER END USERS 
          TABLE 26 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
9 AMNIOTIC PRODUCTS MARKET, BY REGION (Page No. - 87)
    9.1 INTRODUCTION 
          TABLE 27 AMNIOTIC PRODUCTS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 23 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET SNAPSHOT
          TABLE 28 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 29 NORTH AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 30 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 31 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Growing geriatric population and high prevalence of chronic wounds and diabetes to drive market
                                TABLE 32 US: KEY MACRO INDICATORS
                                TABLE 33 US: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 34 US: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 35 US: AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Rising prevalence of target diseases to drive market
                                TABLE 36 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
                                TABLE 37 CANADA: KEY MACRO INDICATORS
                                TABLE 38 CANADA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 39 CANADA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 40 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.3 RECESSION IMPACT ON NORTH AMERICA
    9.3 EUROPE 
          TABLE 41 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
          TABLE 42 PREVALENCE OF DIABETES IN EUROPE, 2019 VS. 2045
          TABLE 43 EUROPE: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 44 EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 45 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 46 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Increasing incidence of diabetes to drive market
                                TABLE 47 GERMANY: KEY MACRO INDICATORS
                                TABLE 48 GERMANY: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 49 GERMANY: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 50 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 High prevalence of diabetes activities to drive market
                                TABLE 51 UK: KEY MACRO INDICATORS
                                TABLE 52 UK: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 53 UK: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 54 UK: AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Government support to drive demand for amniotic products
                                TABLE 55 FRANCE: KEY MACRO INDICATORS
                                TABLE 56 FRANCE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 57 FRANCE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 58 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.4 REST OF EUROPE
                    TABLE 59 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)
                    TABLE 60 REST OF EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 61 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 62 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.5 RECESSION IMPACT ON EUROPE
    9.4 ASIA PACIFIC 
          FIGURE 24 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET SNAPSHOT
          TABLE 63 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 64 ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 65 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 66 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Increasing incidence of diabetes and growth in geriatric population to drive market
                                TABLE 67 CHINA: KEY MACRO INDICATORS
                                TABLE 68 CHINA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 69 CHINA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 70 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Growing geriatric population to drive market
                                TABLE 71 JAPAN: KEY MACRO INDICATORS
                                TABLE 72 JAPAN: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 73 JAPAN: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 74 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.3 REST OF ASIA PACIFIC
                    TABLE 75 REST OF ASIA PACIFIC: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021
                    TABLE 76 REST OF ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 77 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 78 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.4.4 RECESSION IMPACT ON ASIA PACIFIC
    9.5 LATIN AMERICA 
           9.5.1 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
                    TABLE 79 LATIN AMERICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021
                    TABLE 80 LATIN AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 81 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 82 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 GROWTH IN HEALTHCARE INFRASTRUCTURE AND GOVERNMENT INITIATIVES TO DRIVE MARKET
                    TABLE 83 MIDDLE EAST & AFRICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021
                    TABLE 84 MIDDLE EAST & AFRICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 85 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 86 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 123)
     10.1 OVERVIEW 
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 87 OVERVIEW OF STRATEGIES ADOPTED BY KEY AMNIOTIC PRODUCT MARKET PLAYERS
     10.3 MARKET SHARE ANALYSIS, 2022 
             TABLE 88 AMNIOTIC PRODUCTS MARKET: DEGREE OF COMPETITION (2022)
     10.4 REVENUE SHARE ANALYSIS, 2022 
             FIGURE 25 AMNIOTIC PRODUCTS INDUSTRY: REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS, 2020–2022
     10.5 COMPANY EVALUATION QUADRANT 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                        FIGURE 26 MARKET: COMPANY EVALUATION MATRIX, 2022
     10.6 SMALL AND MEDIUM-SIZED ENTERPRISE/STARTUP EVALUATION QUADRANT 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                        FIGURE 27 MARKET: SMALL AND MEDIUM-SIZED ENTERPRISE/ STARTUP EVALUATION MATRIX, 2022
     10.7 COMPETITIVE BENCHMARKING 
             TABLE 89 MARKET: DETAILED LIST OF KEY SMALL AND MEDIUM-SIZED ENTERPRISES/STARTUPS
     10.8 COMPETITIVE SCENARIO 
             10.8.1 PRODUCT LAUNCHES
                        TABLE 90 PRODUCT LAUNCHES
             10.8.2 DEALS
                        TABLE 91 DEALS
             10.8.3 OTHERS
                        TABLE 92 OTHERS
     10.9 COMPANY FOOTPRINT ANALYSIS 
             TABLE 93 COMPANY FOOTPRINT ANALYSIS
             TABLE 94 COMPANY PRODUCT FOOTPRINT
             TABLE 95 COMPANY REGIONAL FOOTPRINT
 
11 COMPANY PROFILES (Page No. - 135)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     11.1 KEY PLAYERS 
             11.1.1 MIMEDX GROUP, INC.
                        TABLE 96 MIMEDX GROUP, INC.: COMPANY OVERVIEW
                        FIGURE 28 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)
             11.1.2 SMITH+NEPHEW
                        TABLE 97 SMITH+NEPHEW: COMPANY OVERVIEW
                        FIGURE 29 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)
             11.1.3 ORGANOGENESIS INC.
                        TABLE 98 ORGANOGENESIS INC.: COMPANY OVERVIEW
                        FIGURE 30 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)
             11.1.4 INTEGRA LIFESCIENCES
                        TABLE 99 INTEGRA LIFESCIENCES: COMPANY OVERVIEW
                        FIGURE 31 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)
             11.1.5 STRYKER
                        TABLE 100 STRYKER: COMPANY OVERVIEW
                        FIGURE 32 STRYKER: COMPANY SNAPSHOT (2022)
             11.1.6 APPLIED BIOLOGICS
                        TABLE 101 APPLIED BIOLOGICS: COMPANY OVERVIEW
             11.1.7 CELULARITY INC.
                        TABLE 102 CELULARITY INC.: COMPANY OVERVIEW
             11.1.8 CORZA OPHTHALMOLOGY
                        TABLE 103 CORZA OPHTHALMOLOGY: COMPANY OVERVIEW
             11.1.9 LUCINA BIOSCIENCES
                        TABLE 104 LUCINA BIOSCIENCES: COMPANY OVERVIEW
             11.1.10 NEXT BIOSCIENCES
                        TABLE 105 NEXT BIOSCIENCES: COMPANY OVERVIEW
             11.1.11 SKYE BIOLOGICS HOLDINGS, LLC
                        TABLE 106 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW
             11.1.12 SURGENEX
                        TABLE 107 SURGENEX: COMPANY OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 BIOTISSUE
             11.2.2 VENTRIS MEDICAL, LLC
             11.2.3 STIMLABS LLC
             11.2.4 VIVEX BIOLOGICS, INC.
             11.2.5 LIFECELL
             11.2.6 NUVISION BIOTHERAPIES LTD
             11.2.7 GENESIS BIOLOGICS, INC.
             11.2.8 SURGILOGIX
             11.2.9 TIDES MEDICAL
             11.2.10 ORTHOFIX US LLC
             11.2.11 ALLOSOURCE
             11.2.12 MERAKRIS THERAPEUTICS, INC.
             11.2.13 MTF BIOLOGICS
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 172)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

 

The study involved four major activities in estimating the current size of the amniotic products market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (Physicians. Ophthalmologists, Orthopedic Surgeons) and supply sides (amniotic product’s manufacturers and distributors).

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Amniotic Products Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2. Tiers of companies are defined based on their total revenue. As of 2020: Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the amniotic products market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the amniotic products industry.

Report Objectives

  • To define, describe, and forecast the global amniotic products market based on types, applications, end users, and region.
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, Latin America, Middle East & Africa
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3.
  • To track and analyze competitive developments such as acquisitions, agreements, new product launches, and partnerships in the amniotic products market. market m

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company.
  • Geographic Analysis:  Further breakdown of the European amniotic products market into specific countries.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 7637
Published ON
Jul, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Amniotic Products Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback